J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 11, Number 10, October 2019, pages 690-695

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice

**Table 1.** Background of Patients
Parameters
Values are n (case numbers) or mean ± SD, and TG is in median and interquartile range. TG: triglyceride; PBG: postprandial blood glucose; FBG: fasting blood glucose; BW: body weight; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CK: creatine kinase; Cre: creatinine; HbA1c: hemoglobin A1c.
Case number	Men: 24, women: 9
Average age	60.2 ± 12.8 years old
Average administration period	3.5 ± 1.7 months
Administration dose	0.1 mg, once daily
Other fibrates	None: 22 cases
Fenofibrates: seven cases; bezafibrates: four cases
Use of statins	None: 24 cases
Statins: nine cases
Baseline TG (non-fasting, mg/dL)	285.0 (210.5 - 423.0) (33)
HDL-C (mg/dL)	46.5 ± 12.5 (32)
LDL-C (mg/dL)	116.4 ± 33.4 (32)
AST (U/L)	32.2 ± 16.5 (33)
ALT (U/L)	36.4 ± 29.0 (33)
CK (U/L)	180.1 ± 162.8 (25)
Cre (mg/dL)	0.8 ± 0.2 (33)
PBG (mg/dL)	120.0 ± 27.0 (29)
FBG (mg/dL)	121.3 ± 13.9 (3)
HbA1c (%)	6.2 ± 0.7 (6)
BW (kg)	76.6 ± 15.6 (26)

Table 1. Background of Patients

Parameters

Values are n (case numbers) or mean ± SD, and TG is in median and interquartile range. TG: triglyceride; PBG: postprandial blood glucose; FBG: fasting blood glucose; BW: body weight; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CK: creatine kinase; Cre: creatinine; HbA1c: hemoglobin A1c.

Case number

Men: 24, women: 9

Average age

60.2 ± 12.8 years old

Average administration period

3.5 ± 1.7 months

Administration dose

0.1 mg, once daily

Other fibrates

None: 22 cases

Fenofibrates: seven cases; bezafibrates: four cases

Use of statins

None: 24 cases

Statins: nine cases

Baseline TG (non-fasting, mg/dL)

285.0 (210.5 - 423.0) (33)

HDL-C (mg/dL)

46.5 ± 12.5 (32)

LDL-C (mg/dL)

116.4 ± 33.4 (32)

AST (U/L)

32.2 ± 16.5 (33)

ALT (U/L)

36.4 ± 29.0 (33)

CK (U/L)

180.1 ± 162.8 (25)

Cre (mg/dL)

0.8 ± 0.2 (33)

PBG (mg/dL)

120.0 ± 27.0 (29)

FBG (mg/dL)

121.3 ± 13.9 (3)

HbA1c (%)

6.2 ± 0.7 (6)

BW (kg)

76.6 ± 15.6 (26)

**Table 2.** Results
Parameters	Baseline	Post data	Changes	P value
Values are n (case numbers) or mean ± SD, and TG is in median and interquartile range. TG: triglyceride; PBG: postprandial blood glucose; FBG: fasting blood glucose; BW: body weight; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CK: creatine kinase; Cre: creatinine; HbA1c: hemoglobin A1c. P < 0.05, P < 0.01, and **P < 0.001.
Baseline TG (non-fasting, mg/dL)	285.0 (210.5 - 423.0) (33)	209.0 (137.0 - 273.0) (31)	-20.8 ± 47.6% (rates)	0.006**
HDL-C (mg/dL)	46.5 ± 12.5 (32)	49.8 ± 12.9 (30)	3.9 ± 10.2 (29)	0.0465*
10.9 ± 20.8% (rates)	0.0091**
LDL-C (mg/dL)	116.4 ± 33.4 (32)	136.1 ± 37.0 (30)	16.6 ± 23.7 (29)	0.0008***
15.8 ± 22.6% (rates)	0.0008***
AST (U/L)	32.2 ± 16.5 (33)	31.9 ± 14.0 (27)	-2.0 ± 13.5 (27)	0.4390
ALT (U/L)	36.4 ± 29.0 (33)	36.3 ± 30.1 (27)	-1.5 ± 18.3 (27)	0.6701
CK (U/L)	180.1 ± 162.8 (25)	135.4 ± 77.4 (16)	-42.3 ± 95.4 (15)	0.1083
Cre (mg/dL)	0.8 ± 0.2 (33)	0.8 ± 0.3 (21)	0.0 ± 0.1 (21)	0.6894
PBG (mg/dL)	120.0 ± 27.0 (29)	123.3 ± 31.7 (22)	0.0 ± 28.1 (22)	0.9940
FBG (mg/dL)	121.3 ± 13.9 (3)	113.3 ± 11.5 (3)	-8.0 ± 4.4 (3)	0.0863
HbA1c (%)	6.2 ± 0.7 (26)	6.4 ± 0.7 (18)	-0.1 ± 0.2 (16)	0.1984
BW (kg)	76.6 ± 15.6 (26)	77.4 ± 15.6 (22)	0.2 ± 1.5 (19)	0.5326

Table 2. Results

Parameters

Baseline

Post data

Changes

P value

Baseline TG (non-fasting, mg/dL)

285.0 (210.5 - 423.0) (33)

209.0 (137.0 - 273.0) (31)

-20.8 ± 47.6% (rates)

0.006**

HDL-C (mg/dL)

46.5 ± 12.5 (32)

49.8 ± 12.9 (30)

3.9 ± 10.2 (29)

0.0465*

10.9 ± 20.8% (rates)

0.0091**

LDL-C (mg/dL)

116.4 ± 33.4 (32)

136.1 ± 37.0 (30)

16.6 ± 23.7 (29)

0.0008***

15.8 ± 22.6% (rates)

0.0008***

AST (U/L)

32.2 ± 16.5 (33)

31.9 ± 14.0 (27)

-2.0 ± 13.5 (27)

0.4390

ALT (U/L)

36.4 ± 29.0 (33)

36.3 ± 30.1 (27)

-1.5 ± 18.3 (27)

0.6701

CK (U/L)

180.1 ± 162.8 (25)

135.4 ± 77.4 (16)

-42.3 ± 95.4 (15)

0.1083

Cre (mg/dL)

0.8 ± 0.2 (33)

0.8 ± 0.3 (21)

0.0 ± 0.1 (21)

0.6894

PBG (mg/dL)

120.0 ± 27.0 (29)

123.3 ± 31.7 (22)

0.0 ± 28.1 (22)

0.9940

FBG (mg/dL)

121.3 ± 13.9 (3)

113.3 ± 11.5 (3)

-8.0 ± 4.4 (3)

0.0863

HbA1c (%)

6.2 ± 0.7 (26)

6.4 ± 0.7 (18)

-0.1 ± 0.2 (16)

0.1984

BW (kg)

76.6 ± 15.6 (26)

77.4 ± 15.6 (22)

0.2 ± 1.5 (19)

0.5326

**Table 3.** TG on Conditions
	Baseline	Post data	Changes	P value
Values are n (case numbers) or mean ± SD, and TG is in median and interquartile range. TG: triglyceride. P < 0.05, P < 0.01, and **P < 0.001.
TG ≥ 150 (mg/dL)	299.0 (214.0 - 423.5) (32)	218.5 (147.5 - 277.3) (30)	-21.6 ± 48.2% (rates)	0.006**
TG ≥ 200 (mg/dL)	354.5 (240.0 - 452.5) (28)	236.5 (155.8 - 292.0) (26)	-26.5 ± 48.3% (rates)	0.002**
TG (using fibrates for the first time) (mg/dL)	372.0 (211.0 - 433.5) (22)	208.5 (153.8 - 285.8) (20)	-28.4 ± 37.4% (rates)	0.006**
TG (changing from other fibrates) (mg/dL)	254.0 (208.0 - 366.0) (11)	236.0 (119.0 - 268.0) (11)	-7.0 ± 61.7% (rates)	0.465
TG ≥ 200 and using fibrates for the first time (mg/dL)	411.0 (237.0 - 462.0) (19)	209.0 (172.5 - 294.0) (17)	-34.5 ± 37.2% (rates)	0.006**
TG (mg/dL) with none use of statins	299.0 (205.8 - 466.3) (24)	218.5 (135.8 - 269.3) (24)	-25.4 ± 36.1% (rates)	0.003**
TG (mg/dL) with use of statins	267.0 (215.0 - 412.5) (9)	206.0 (130.5 - 317.5) (9)	-9.5 ± 69.7% (rates)	0.570

Table 3. TG on Conditions

Baseline

Post data

Changes

P value

Values are n (case numbers) or mean ± SD, and TG is in median and interquartile range. TG: triglyceride. *P < 0.05, **P < 0.01, and ***P < 0.001.

TG ≥ 150 (mg/dL)

299.0 (214.0 - 423.5) (32)

218.5 (147.5 - 277.3) (30)

-21.6 ± 48.2% (rates)

0.006**

TG ≥ 200 (mg/dL)

354.5 (240.0 - 452.5) (28)

236.5 (155.8 - 292.0) (26)

-26.5 ± 48.3% (rates)

0.002**

TG (using fibrates for the first time) (mg/dL)

372.0 (211.0 - 433.5) (22)

208.5 (153.8 - 285.8) (20)

-28.4 ± 37.4% (rates)

0.006**

TG (changing from other fibrates) (mg/dL)

254.0 (208.0 - 366.0) (11)

236.0 (119.0 - 268.0) (11)

-7.0 ± 61.7% (rates)

0.465

TG ≥ 200 and using fibrates for the first time (mg/dL)

411.0 (237.0 - 462.0) (19)

209.0 (172.5 - 294.0) (17)

-34.5 ± 37.2% (rates)

0.006**

TG (mg/dL) with none use of statins

299.0 (205.8 - 466.3) (24)

218.5 (135.8 - 269.3) (24)

-25.4 ± 36.1% (rates)

0.003**

TG (mg/dL) with use of statins

267.0 (215.0 - 412.5) (9)

206.0 (130.5 - 317.5) (9)

-9.5 ± 69.7% (rates)

0.570

**Table 4.** LDL-C on Conditions
	Baseline	Post data	Changes	P value
Values are n (case numbers) or mean ± SD, and TG is in median and interquartile range. TG: triglyceride. P < 0.05, P < 0.01, and **P < 0.001.
LDL (mg/dL) with no use of statins	119.7 ± 36.0 (23)	147.4 ± 34.3 (21)	23.2 ± 23.7 (21)	0.003**
TG: 285.0 (205.0 - 481.0)	22.1 ± 22.9% (rates)	0.0004***
LDL (mg/dL) with use of statins	107.9 ± 25.4 (9)	109.8 ± 30.2 (9)	1.9 ± 16.6 (9)	0.7414
TG: 267.0 (215.0 - 412.5)	1.9 ± 15.0% (rates)	0.7115

Table 4. LDL-C on Conditions

Baseline

Post data

Changes

P value

Values are n (case numbers) or mean ± SD, and TG is in median and interquartile range. TG: triglyceride. *P < 0.05, **P < 0.01, and ***P < 0.001.

LDL (mg/dL) with no use of statins

119.7 ± 36.0 (23)

147.4 ± 34.3 (21)

23.2 ± 23.7 (21)

0.003**

TG: 285.0 (205.0 - 481.0)

22.1 ± 22.9% (rates)

0.0004***

LDL (mg/dL) with use of statins

107.9 ± 25.4 (9)

109.8 ± 30.2 (9)

1.9 ± 16.6 (9)

0.7414

TG: 267.0 (215.0 - 412.5)

1.9 ± 15.0% (rates)

0.7115